Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome

Clinical Transplantation

Volumn 26, Issue 5, 2012, Pages

  El Atrache, Mazen M ^a   Abouljoud, Marwan S ^a   Divine, George ^a   Yoshida, Atsushi ^a   Kim, Dean Y ^a   Kazimi, Marwan M ^a   Moonka, Dilip ^a   Huang, Mary A ^a   Brown, Kim ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Cryptogenic cirrhosis; Liver transplantation; Metabolic disease; Non alcoholic steatohepatitis; Recurrence

Indexed keywords

INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; CRYPTOGENIC CIRRHOSIS; END STAGE LIVER DISEASE; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RECURRENT DISEASE; RETRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84867595173     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12014     Document Type: Article

References (29)

1. Ludwig J, Viggiano TR, McGill DB. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proc 1980: 55: 434.
2. Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 2004: 4: 686.
3. Seo S, Maganti K, Khehra M. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 2007: 13: 844.
4. Kim WR, Poterucha JJ, Porayko MK et al. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996: 62: 1802.
5. Malik SM, deVera ME, Fontes P. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 2009: 9: 782.
6. Ong JP, Younossi ZM. Nonalcoholic fatty liver disease (NAFLD)-two decades later: are we smarter about its natural history? Am J Gastroenterol 2003: 98: 1915.
7. Harrison SA, Torgerson S, Hayashi PH. The natural history on nonalcoholic fatty liver disease: a clinical histopathologic study. Am J Gastroenterol 2003: 98: 2042.
8. Ong J, Younossi ZM, Reddy V. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001: 7: 797.
9. Caldwell SH, Oelsner DH, Iezzoni JC et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999: 29: 664.
10. Ponawala A, Nair S, Thuluvath P. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis. Hepatology 2000: 32: 689.
11. Czaja AJ. Recurrence of nonalcoholic steatohepatitis after liver transplantation. Liver Transpl Surg 1997: 3: 185.
12. Molloy RM, Komorowski R, Varma RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg 1997: 3: 177.
13. Contos MJ, Cales W, Sterling RK. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001: 7: 363.
14. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005: 112: 2735.
15. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005: 28: 2745.
16. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004: 2: 1048.
17. O'Leary JG, Landaverde C, Jennings L, Goldstein RM, Davis GL. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol 2011: 9: 700.
18. Malik SM, deVera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl 2009: 15: 1843.
19. Tankurt E, Biberoglu S, Ellidokuz E, Hekimsoy Z. Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis. J Hepatol 1999: 31: 963.
20. Angula P. Nonalcoholic fatty liver disease and liver transplantation 2006. Liver Transpl 2006: 12: 523.
21. Marchesini G, Brizi M, Morselli Labate AM, Bianchi G. Association of non-alcoholic fatty liver disease to insulin resistance. Am J Med 1999: 107: 450.
22. Day CP, James OFW. Steatohepatitis: a tale for two "hits"? Gastroenterology 1998: 114: 842.
23. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010: 16: 431.
24. Kniepeiss D, Iberer F, Schaffellner S et al. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin Transpl 2004: 18: 642.
25. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002: 35: 373.
26. Pagano G, Pacini G, Musso G et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002: 35: 367.
27. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007: Art. No. CD005166.
28. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010: 362: 1675.
29. Raoufi M, Ma C, Ormsby A et al. The role of post-reperfusion biopsy in the era of extended criteria donor. Liver Transpl 2009: 15(Suppl. 1): pS266.